Romain Larive

Dr. Romain Larive

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2012 in Science Signaling
Verified
Journal Article
Closed access
PDF file
CCCarmen Citterio
Carmen Citterio
MMMauricio Menacho-Márquez
Mauricio Menacho-Márquez
RGRamon Garcia-Escudero
Ramon Garcia-Escudero
RLRomain Larive
Romain Larive
OBOlga Barreiro
Olga Barreiro
Xosé BusteloXosé Bustelo
Xosé Bustelo
The guanosine triphosphatases of the Rho and Rac subfamilies regulate protumorigenic pathways and are activated by guanine nucleotide exchange factors (Rho GEFs), which could be potential targets for anticancer therapies. We report that two Rho GEFs, Vav2 and Vav3, play synergistic roles in breast cancer by sustaining tumor growth, neoangiogenesis, and many of the steps involved in lung-specific metastasis. The involvement of Vav proteins in these processes did not correlate with Rac1 and RhoA activity or cell migration, implying the presence of additional biological programs. Microarray analyses revealed that Vav2 and Vav3 controlled a vast transcriptional program in breast cancer cells through mechanisms that were shared between the two proteins, isoform-specific or synergistic. Furthermore, the abundance of Vav-regulated transcripts was modulated by Rac1-dependent and Rac1-independent pathways. This transcriptome encoded therapeutically targetable proteins that played nonredundant roles in primary tumorigenesis and lung-specific metastasis, such as integrin-linked kinase (Ilk), the transforming growth factor–β family ligand inhibin βA, cyclooxygenase-2, and the epithelial cell adhesion molecule Tacstd2. It also contained gene signatures that predicted disease outcome in breast cancer patients. These results identify possible targets for treating breast cancer and lung metastases and provide a potential diagnostic tool for clinical use.

24 January 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
CNCécile Naudin
Cécile Naudin
ASAudrey Sirvent
Audrey Sirvent
CLCédric Leroy
Cédric Leroy
RLRomain Larive
Romain Larive
VSValérie Simon
Valérie Simon
serge rocheserge roche
serge roche
The adaptor SLAP is a negative regulator of receptor signalling in immune cells but its role in human cancer is ill defined. Here we report that SLAP is abundantly expressed in healthy epithelial intestine but strongly downregulated in 50% of colorectal cancer. SLAP overexpression suppresses cell tumorigenicity and invasiveness while SLAP silencing enhances these transforming properties. Mechanistically, SLAP controls SRC/EPHA2/AKT signalling via destabilization of the SRC substrate and receptor tyrosine kinase EPHA2. This activity is independent from CBL but requires SLAP SH3 interaction with the ubiquitination factor UBE4A and SLAP SH2 interaction with pTyr594-EPHA2. SRC phosphorylates EPHA2 on Tyr594, thus creating a feedback loop that promotes EPHA2 destruction and thereby self-regulates its transforming potential. SLAP silencing enhances SRC oncogenicity and sensitizes colorectal tumour cells to SRC inhibitors. Collectively, these data establish a tumour-suppressive role for SLAP in colorectal cancer and a mechanism of SRC oncogenic induction through stabilization of its cognate substrates.

4 May 2009 in Oncogene
Verified
Journal Article
Closed access
RLRomain Larive
Romain Larive
SUS Urbach
S Urbach
JPJ Poncet
J Poncet
PJP Jouin
P Jouin
GMG Mascré
G Mascré
NBNadir Bettache
Nadir Bettache

15 June 2012 in Molecular Biology of the Cell
Verified
Journal Article
Open access
RLRomain Larive
Romain Larive
AAAntonio Abad
Antonio Abad
CCClara M. Cardaba
Clara M. Cardaba
THTeresa Hernández
Teresa Hernández
MCMarta Cañamero
Marta Cañamero
Xosé BusteloXosé Bustelo
Xosé Bustelo
R-Ras2/TC21 is a GTPase with high sequence and signaling similarity with Ras subfamily members. Although it has been extensively studied using overexpression studies in cell lines, its physiological role remains poorly characterized. Here we used RRas2-knockout mice expressing β-galactosidase under the regulation of the endogenous RRas2 promoter to investigate the function of this GTPase in vivo. Despite its expression in tissues critical for organismal viability, RRas2−/−mice show no major alterations in viability, growth rates, cardiovascular parameters, or fertility. By contrast, they display a marked and specific defect in the development of the mammary gland during puberty. In the absence of R-Ras2/TC21, this gland forms reduced numbers of terminal end buds (TEBs) and ductal branches, leading to a temporal delay in the extension and arborization of the gland tree in mammary fat pads. This phenotype is linked to cell-autonomous proliferative defects of epithelial cells present in TEBs. These cells also show reduced Erk activation but wild type–like levels of phosphorylated Akt. Using compound RRas2-, HRas-, and NRas-knockout mice, we demonstrate that these GTPases act in a nonsynergistic and nonadditive manner during this morphogenic process.

14 May 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
RLRomain Larive
Romain Larive
GMGiulia Moriggi
Giulia Moriggi
MMMauricio Menacho-Márquez
Mauricio Menacho-Márquez
MCMarta Cañamero
Marta Cañamero
EÁEnrique de Álava
Enrique de Álava
Xosé BusteloXosé Bustelo
Xosé Bustelo
R-Ras2 is a transforming GTPase that shares downstream effectors with Ras subfamily proteins. However, little information exists about the function of this protein in tumorigenesis and its signalling overlap with classical Ras GTPases. Here we show, by combining loss- and gain-of-function studies in breast cancer cells, mammary epithelial cells and mouse models, that endogenous R-Ras2 has a role in both primary breast tumorigenesis and the late metastatic steps of cancer cells in the lung parenchyma. R-Ras2 drives tumorigenesis in a phosphatidylinostiol-3 kinase (PI3K)-dependent and signalling autonomous manner. By contrast, its prometastatic role requires other priming oncogenic signals and the engagement of several downstream elements. R-Ras2 function is required even in cancer cells exhibiting constitutive activation of classical Ras proteins, indicating that these GTPases are not functionally redundant. Our results also suggest that application of long-term R-Ras2 therapies will result in the development of compensatory mechanisms in breast tumours.

1 March 2010 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
RLRomain Larive
Romain Larive
LBLaurent Baisamy
Laurent Baisamy
SUSerge Urbach
Serge Urbach
Peter CoopmanPeter Coopman
Peter Coopman
NBNadir Bettache
Nadir Bettache